Skip to main content
. 2016 Sep 1;7(42):67956–67965. doi: 10.18632/oncotarget.11815

Figure 3. Effect of therapies against IL-6 signaling on the growth of different breast cancer PDXs.

Figure 3

A. PDXs were orthotopically implanted into NOD/SCID mice and treated with two anti-IL-6 signaling therapies (anti-IL-6 or anti-IL6RA blocking antibodies). Note that, when using anti-IL-6, in order to analyze the role of autocrine IL-6, PDXs were treated with anti-mouse IL-6, which does not cross-react with human IL-6 and, thus, does not affect the IL-6 produced by human tumor cells. Anti-IL-6RA antibody does not recognize mouse IL-6 receptor [27]. Tumor volumes were determined at the indicated time points and expressed as averages. The sensitivity of PDX118 to inhibition of IL-6 signaling has been determined elsewhere [14]. B. Basal levels of IL-6, IL-6RA and phospho-STAT3 were determined in lysates from the indicated PDX tumors. The results are expressed as averages of three independent tumors ± SD.